“Increasing Adoption of Biologic Therapies”
A key trend in the sarilumab market is the increasing adoption of biologic therapies for the treatment of autoimmune diseases. Sarilumab, a monoclonal antibody and interleukin-6 (IL-6) receptor antagonist, has gained significant traction in managing conditions such as rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA). For instance, in 2021, Sanofi and Regeneron expanded the approval of sarilumab to include the treatment of active pJIA in children, further driving its market penetration. This trend is driven by the growing demand for more effective and targeted therapies, particularly in patients who have not responded to traditional disease-modifying antirheumatic drugs (DMARDs). Additionally, increasing awareness and improving healthcare infrastructure, especially in emerging markets, are contributing to the widespread use of biologics such as sarilumab. As the number of patients diagnosed with autoimmune diseases continues to rise globally, the sarilumab market is poised for continued growth and expansion.
